Latest Press Releases

Derm-biome Pharmaceuticals' Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial: Drug Prevents the Development of Precancerous Skin Conditions and Treats Existing Skin Cancers With No Observable Side Effects

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 ...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and ...

Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

SAN FRANCISCO and ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma ...

IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis

MONROVIA, Calif. , Feb. 18, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and ...

Press Releases

Premium Press Releases »

Derm-biome Pharmaceuticals' Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial: Drug Prevents the Development of Precancerous Skin Conditions and Treats Existing Skin Cancers With No Observable Side Effects

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

Press Releases »

Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis

Medindia Newsletters